SCHAUMBURG, Ill., Aug. 31, 2011 (CRWENewswire) — Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a specialty pharmaceutical company, today announced U.S. FDA approval of its Orphenadrine Citrate Injection, USP, a skeletal muscle relaxant. Sagent’s orphenadrine will be offered in 60 mg per 2 mL single-dose, latex-free vials. According to 2011 IMS data, the U.S. injectable market for orphenadrine approximated $4.3 million. As with all products in Sagent’s portfolio, orphenadrine features the company’s PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors. Sagent expects to launch orphenadrine in the third quarter of 2011.
“We are pleased to add orphenadrine to our continuously expanding product portfolio,” said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. “This is another example of our commitment to the market by rapidly introducing a broad portfolio of quality injectable products.”
About Orphenadrine Citrate Injection, USP
Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.
Detailed information about the indications, warnings, complete side effect profile, and full prescribing information will be available in the package insert. Please visit www.SagentPharma.com for more information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
Forward-Looking Statement
Statements contained in this press release contain forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give Sagent’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business as of the date of this release. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Sagent’s expectations are not predictions of future performance, and future results may substantially differ from current expectations based upon a variety of factors, risks and uncertainties affecting Sagent’s business, including, among others, the impact of competitive products and pricing and actions by Sagent’s competitors with respect thereto; the timing of product launches; compliance with FDA and other governmental regulations by Sagent and its third party manufacturers; changes in laws and regulations; and such other risks detailed in Sagent’s periodic public filings with the Securities and Exchange Commission, including but not limited to Sagent’s most recent quarterly report on Form 10-Q and Sagent’s IPO prospectus filed on April 21, 2011. Sagent disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.
Contact:
INVESTOR CONTACT:
Ronald Pauli, Sagent
(847) 908-1604
MEDIA CONTACT:
Geoff Curtis, WCG
(312) 646-6298
Source: Sagent Pharmaceuticals, Inc.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
No comments:
Post a Comment